98%
921
2 minutes
20
Trained immunity is a long-term increase in responsiveness of innate immune cells, induced by certain infections and vaccines. During the last 3 years of the COVID-19 pandemic, vaccines that induce trained immunity, such as BCG, MMR, OPV, and others, have been investigated for their capacity to protect against COVID-19. Further, trained immunity-inducing vaccines have been shown to improve B and T cell responsiveness to both mRNA- and adenovirus-based anti-COVID-19 vaccines. Moreover, SARS-CoV-2 infection itself induces inappropriately strong programs of trained immunity in some individuals, which may contribute to the long-term inflammatory sequelae. In this review, we detail these and other aspects of the role of trained immunity in SARS-CoV-2 infection and COVID-19. We also examine the learnings from the trained immunity studies conducted in the context of this pandemic and discuss how they may help us in preparing for future infectious outbreaks.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265767 | PMC |
http://dx.doi.org/10.1016/j.chom.2023.05.004 | DOI Listing |
Curr Med Chem
August 2025
Laboratory of Molecular Genetic Modeling of Inflammaging, Institute of General Pathology and Pathophysiology, 8, Baltiiskaya Street, 125315 Moscow, Russia.
Elife
September 2025
Department of Pediatrics, Division of Infectious Diseases, and Stem Cells and Regenerative Medicine Center, Baylor College of Medicine and Texas Children's Hospital, Houston, United States.
Human and murine studies reveal that innate immune cells are able to mount enhanced responses to pathogens after primary inflammatory exposure. Innate immune memory has been shown to last for months to years, longer than the lifespan of most innate immune cells. Indeed, long-lived hematopoietic stem and progenitor cells (HSPCs) serve as a cellular reservoir for innate immune memory.
View Article and Find Full Text PDFAdv Healthc Mater
September 2025
Nanoengineered Systems Laboratory, UCL Mechanical Engineering, University College London, London, WC1E 7JE, UK.
Kidney transplant recipients face a high risk of acute rejection (AR), where the immune system attacks the transplanted organ. Current diagnostics rely on invasive biopsies with procedural risks, costs, and limited temporal resolution. While urinary chemokines CXCL9 and CXCL10 are promising non-invasive AR biomarkers, clinical adoption is limited by labor-intensive detection and lack of point-of-care (POC) solutions.
View Article and Find Full Text PDFFront Immunol
August 2025
Department of Biology, Benedict College, Columbia, SC, United States.
Immunology
September 2025
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.
Traditional DNA vaccines, typically administered via intramuscular injection with electroporation (IM-E), often cause discomfort and require trained personnel. Addressing these challenges, we developed multivalent DNA vaccines targeting both intracellular mature virion (IMV) and extracellular enveloped virion (EEV) proteins of the monkeypox virus (MPXV), designated as M2 (A29L, B6R), M3 (A29L, B6R, M1R) and M4 (A29L, B6R, M1R, A35R). These vaccine constructs were formulated into dissolvable microneedle array patches (D-MAPs) for intradermal delivery.
View Article and Find Full Text PDF